EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

NLX ‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy

Per Svenningsson iD, Per Odin, Filip Bergquist iD, Karin Wirdefeldt, Dag Nyholm iD, Mattias Andréasson, Ioanna Markaki iD, Anders C Johansson, Måns Jergil, Christopher Jankosky, Mark A Varney, Fabienne Herbrecht und 2 weitere

Movement Disorders · 2025-06 · 40 (6) · 1134-1142

DOI: 10.1002/mds.30175 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 17.03.2025. Verfasst von Per Svenningsson und 13 weiteren Autor:innen. Beteiligte Einrichtung: ASC Torsplan, Stockholm, Sweden. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Dyskinesia, Drug-Induced, Antiparkinson Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research, Parkinson's UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa‐induced dyskinesia (LID) in Parkinson's disease (PD) is associated with ‘false neurotransmitter’ release of dopamine from serotonin (5‐HT) neurons. NLX‐112 is a first‐in‐class, highly selective 5‐HT 1A receptor agonist which counteracts LIDs in experimental PD models.

Objectives

The primary objective was to evaluate the safety and tolerability of NLX‐112 compared with placebo in people with PD. The secondary objective was to assess the preliminary efficacy of NLX‐112 in reducing LID and its effects on PD symptoms.

Methods

Participants received NLX‐112 or placebo (2:1 ratio) alongside stable Parkinson's medications, with 22 participants completing the study. Dosing was up‐titrated over 28 days to 2 mg/day (1 mg twice daily), stabilized for 14 days (to day 42), and down‐titrated for 14 days. Efficacy was measured using the Unified Dyskinesia Rating Scale (UDysRS), Unified Parkinson's Disease Rating Scale (UPDRS), and Clinical Global Impression of Change (CGI‐C) following a levodopa challenge (150% of usual dose).

Results

Adverse events (AEs) were mainly central nervous system (CNS)‐related and mostly occurred during up‐titration, with no serious AEs in the NLX‐112 group. There were no treatment‐induced clinically significant changes in vital signs, electrocardiogram, or laboratory parameters. NLX‐112 reduced LID from baseline levels: at day 42, UDysRS total score decreased by 6.3 points, whereas placebo group changes were not significant (−2.4). NLX‐112 also reduced parkinsonism from baseline values: UPDRS Part 3 scores decreased by 3.7 points, whereas placebo group changes were non‐significant (+0.1). In CGI‐C assessment, the NLX‐112 group showed greater improvement than the placebo group (53% vs. 29%).

Conclusion

These results support further clinical investigation of NLX‐112 for treatment of PD LID. © 2025 Neurolixis SAS. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaDyskinesia, Drug-InducedAntiparkinson AgentsSerotonin 5-HT1 Receptor AgonistsHumansFemaleMaleMiddle AgedAgedDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

5‐HT1A receptorNLX‐112Parkinson's diseasedyskinesialevodopaserotonin

Substanzen

LevodopaAntiparkinson AgentsSerotonin 5-HT1 Receptor Agonists

Autor:innen und Institutionen

  • ASC Torsplan, Stockholm, Sweden.
  • Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
  • Sahlgrenska Hospital, Gothenburg, Sweden.
  • Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden.
  • Department of Neurology, Karolinska University Hospital, Solna, Sweden.
  • Uppsala University, Uppsala, Sweden.

ORCID-Profile: Per Svenningsson, Filip Bergquist, Dag Nyholm, Ioanna Markaki

Förderung

  • Michael J. Fox Foundation for Parkinson's Research
  • Parkinson's UK

Zitieren

APA

Svenningsson, P., Odin, P., Bergquist, F., Wirdefeldt, K., Nyholm, D., Andréasson, M., Markaki, I., Johansson, A. C., Jergil, M., Jankosky, C., Varney, M. A., Herbrecht, F., Johnson, S. A., & Newman-Tancredi, A. (2025). NLX ‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy. Movement Disorders, 40(6), 1134-1142. https://doi.org/10.1002/mds.30175

Vancouver

Svenningsson P, Odin P, Bergquist F, Wirdefeldt K, Nyholm D, Andréasson M, et al. NLX ‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy. Movement Disorders. 2025;40(6):1134-1142. doi:10.1002/mds.30175

BibTeX
@article{Svenningsson2025,
  author = {Svenningsson, Per and Odin, Per and Bergquist, Filip and Wirdefeldt, Karin and Nyholm, Dag and Andréasson, Mattias and Markaki, Ioanna and Johansson, Anders C and Jergil, Måns and Jankosky, Christopher and Varney, Mark A and Herbrecht, Fabienne and Johnson, Steven A and Newman-Tancredi, Adrian},
  title = {NLX ‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy},
  journal = {Movement Disorders},
  year = {2025},
  volume = {40},
  number = {6},
  pages = {1134--1142},
  doi = {10.1002/mds.30175}
}
Kostenlos starten →